INTRODUCTION
Platelet membrane glycoprotein IIb (GPIIb)' and glycoprotein IlIa (GPIIIa) are major components of the platelet plasma membrane that may mediate plateletplatelet interactions (1, 2) . GPIIb and GPIIIa are markedly diminished to absent in platelets in Glanzmann's thrombasthenia, a hereditary bleeding disorder characterized by defective platelet aggregation. An IgG alloantibody isolated from a polytransfused thrombasthenic patient interacts with GPIIb and GPIIIa (3) and induces a thrombasthenia-like state in normal platelets (4, 5) . ADP, epinephrine, and thrombin induce fibrinogen binding to normal platelets, which correlates with platelet aggregability (6) (7) (8) (9) . Thrombasthenic platelets do not bind fibrinogen (7, 9) . These observations suggest that GPIIb and/or GPIIIa are involved in platelet fibrinogen receptor function. We have recently reported the isolation of purified GPIIb Received for publication 7 August 1981 and in revised form 19 October 1981. 1 Abbreviations used in this paper: ELISA, enzyme-linked immunosorbent assay; GP, glycoproteins; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
and GPIIIa and the generation of monospecific antisera to these membrane proteins (10) . In this report, we present evidence demonstrating complex formation of GPIIb and GPIIIa with purified human fibrinogen.
METHODS
Materials. Lentil lectin (lens culinaris hemagglutinin), glucosamine, mannosamine, N-acetyl glucosamine, N-acetyl mannosamine, arginine, glycine, p-nitrophenyl phosphate, and type VII calf mucosa alkaline phosphatase were obtained from Sigma Chemical Co., St. Louis, Mo. Protein A was obtained from Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J. Microtitration plates and a Titertek Multiscan photometer were purchased from Flow Laboratories, Inc., Rockville, Md. All reagents were of analytical grade.
Protein purification. Chromatographically pure peak 1 human fibrinogen prepared by the method of Finlayson and Mosesson (11) (kindly supplied by Dr. M. Mosesson, Downstate Medical Center, New York) was free of factor XIII, plasminogen, factor VIII antigen (VIII:AGN), and fibronectin as determined by lack of reactivity using monospecific antisera to these potential contaminants in an enzyme-linked immunosorbent assay (ELISA). The clottability of this fibrinogen was -96%. The protein migrated as a single band on 5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with an estimated M, of 330,000. The reduced protein in SDS-PAGE revealed a typical distribution of Aa, B,B, and y chains with absence of degradation products. When chromatographed on a Sepharose CL-6B column (1.5 X 45 cm) in 0.25 M NaCl, 0.05 M Tris-HCI, pH 8.6, fibrinogen eluted as a single sharp peak indicating freedom from detectable quantities of fibrin monomers (6) . Plasminogen isolated from plasma by lysine affinity chromatography (12) and gel filtration chromatography was kindly provided by Dr. Peter Harpel, Cornell University Medical College, New York. Factor VIII:AGN and fibronectin were isolated from human plasma as described (13, 14) . Purified human albumin was obtained from Calbiochem-Behring Corp., American Hoechst, San Diego, Calif.
Platelet membrane GPIIb and GPIIIa were isolated and purified using lentil lectin affinity chromatography and electrophoretic elution from SDS-PAGE gels as described (10) . Platelet GPIb was prepared as described (15 Washed platelets were incubated with thrombin in the presence of 1 mM EDTA without stirring. The platelets were removed by centrifugation at 8370 g for 3 min using a Beckman microfuge (Beckman Instruments, Inc., Fullerton, Calif.). The supernate was incubated with 10% by volume of insoluble antifibrinogen beads. After reduction on SDS-PAGE, this protein mixture contained major bands at Mr 185,000 (thrombospondin) and at M, 68,000, probably representing GPV fragment (17) . Platelet factor 4 and ,B-thromboglobulin were also detected at the lower Mr range.
Human erythrocyte membranes were prepared according to the method of Dodge et al. (18) . The membrane proteins were solubilized with 1% sodium deoxycholate, and lentil lectin affinity chromatography was performed as described for platelet membrane proteins (10) . Densitometric scans of Coomassie Blue-stained SDS-PAGE gels were carried out in a Gilford model 240 spectrophotometer equipped with a gel scanning attachment (Gilford Instrument Laboratories, Inc., Oberlin, Ohio) and a Densicord recorder equipped with an integrator (Photovolt Corp., New York).
Antisera. Individual monospecific antisera have been raised in rabbits to the separate isolated GPIIb and GPIIIa (10) . The antisera were absorbed with washed platelets from a patient with classical Glanzmann's thrombasthenia. By two-dimensional immunoelectrophoresis (19) anti-GPIIb reacted with a single antigen of apparent Mr 140,000 in a mixture of solubilized platelet membrane proteins. AntiGPIIIa similarly reacted with a single antigen of apparent Mr 95,000 in a mixture of solubilized platelet membrane proteins. The antisera either singly or in combination failed to react with fibrinogen, albumin, fibronectin, plasminogen, Factor VIII-AGN, platelet GPIb or a crude thrombospondin mixture. For these studies an ELISA system was used in which the antigen tested was coated at concentrations of 1-6 gg/ml and probed with anti-GPIIb and/or anti-GPIIIa -y globulin solutions (1 mg/ml) in varying dilutions from 1:50 to 1:1,000. Antiplasminogen, antifibrinogen, and antialbumin sera were obtained from Calbiochem-Behring Corp. Anti-GPIb was prepared as described (20) . Antierythrocyte membrane sera were obtained from Accurate Chemical and Scientific Corp., Hicksville, N. Y. -y-globulin fractions and Fab'2 fragments of antisera were prepared as described (20) . Antifibrinogen 'y-globulin was coupled to CNBR-activated sepharose 4B beads as described (21) .
ELISA. The performance of the assay was essentially as described by Voller et al. (22) . Microtitration plates were coated with purified human fibrinogen. 0.2-ml portions of the fibrinogen in the bicarbonate coating buffer (0.1 M sodium carbonate, pH 9.6, 0.02% NaNs) were incubated in a humid chamber overnight at 4°C. Optimum binding occurred at fibrinogen concentrations of [4] [5] [6] ,g/ml. Contents of the microtitration plates were removed and the wells washed three times for 3 min each in Tris-Tween buffer (0.01 M Tris, 0.15 M NaCl, pH 7.4 with 0.5 mM CaCl2, containing 0.05% Tween 20) . The solutions containing the partially purified platelet GPIIb and GPIIIa (lentil lectin affinity column eluate) (10) were diluted in Tris-Tween buffer and added in duplicate to coated wells and the plates incubated overnight at 4°C in a humid chamber. The washing procedure was repeated and a mixture of anti-GPIIb and anti-GPIIIa -y-globulin (1 mg/ml), each diluted to final concentration of 1:100 in Tris-Tween buffer, was added for 24 h, 4°C. The washing procedure was repeated and the alkaline phosphatase-labeled protein A prepared as described below was added for 3-h incubation in a humid chamber at 4°C. The wells were emptied, the wash step repeated, and 0.2 ml of the substrate p-nitrophenyl phosphate (1 mg/ml in 10% diethanolamine buffer, pH 9.8) was added. The color development was followed at 5-15-min intervals by repeated readings at 405 nm in a Titertek Multiscan photometer. Color development with time was plotted and the best fit curve was calculated by linear regression analysis. The formation of the GPIIb-GPIIIa-fibrinogen complex was expressed as the enzymatic activity of the bound alkaline phosphatase (AA405 min-').
Alkaline phosphatase-labeled protein A. Protein A was labeled with alkaline phosphatase as described by Engvall (23) . The labeled protein was stored at 4°C with 1% bovine serum albumin and 0.02% NaN3 in Tris buffered saline, pH 7.4. The activity of the labeled protein A was assessed by coating the microtitration plates with fibrinogen (1-6 ,g/ ml) in coating buffer for 18 h in a humid chamber at 4°C. After washing three times for 3 min each in Tris-Tween, dilutions of fibrinogen antisera in Tris-Tween were added for 18 h. The washing step was repeated and Protein Aalkaline phosphatase (0.125 mg/ml) in various dilutions of Tris-Tween were added for 3 h. The wash step was again repeated and the substrate added. Maximum color developed using protein A-alkaline phosphatase at 1:1,000 dilution.
Determination of protein coating efficiency on microtitration plate. Purified human fibrinogen, fibronectin, plasminogen, VIII-AGN, and GPIIb-GPIIIa mixtures were labeled with 1125 using the modified chloramine-T method (6) . Microtitration plates were coated in duplicate with 0.2-ml portions of the labeled proteins at increasing concentrations in the bicarbonate coating buffer at 4°C overnight as described above. After washing three times with Tris-Tween buffer, each well was cut out, radioactivity of the coated protein counted, and the coating efficiency for each protein was determined. The saturating amount of proteins that could be coated per well were 0.7 pm (fibrinogen), 1 Using 125I-labeled platelet glycoproteins, the actual amount of GPIIb and GPIIIa bound to the plastic well was determined at each concentration of protein added, and this was correlated with color generated in the ELISA (Fig. 1) . It should be noted that no differences in reactivity with specific antibody were noted when nonlabeled glycoproteins were compared to '25I-labeled glycoproteins.
Complex formation of GPIIb-GPIIIa with fibrinogen. GPIIb and GPIIIa attached and formed a complex with the purified fibrinogen passively adsorbed and the color generated in the ELISA. The radiolabeled glycoprotein mixture varying from 0.5 to 12 ug/ml in coating buffer was applied to the plastic wells for 18 h at 4°C. After washing, a mixture of anti-GPIIb and anti-GPIIIa -y-globulin (10 ug/ml each) was added for 24 h at 4°C. After washing, alkaline phosphatase-labeled protein A (0.125 Mg/ml) was added for 3 h at room temperature. After washing the substrate p-nitrophenyl phosphate was added and color development followed in a Titertek Multiscan photometer. The reaction was expressed as the enzymatic activity of the bound alkaline phosphatase (10' X AA405 min-'). The wells were then washed, cut out, and counted and the amount of protein in each well determined. Y=1.116x + 13.73, R=0.97.
to the wells of the plastic microtitration plate. The formation of the GPIIb-GPIIIa complex with adsorbed fibrinogen was dependent on the presence of Ca2 . In the absence of added Ca2+, no significant complex formation was demonstrated using a mixture of antiGPIIb and anti-GPIIIa -y-globulin (Table I) . Maximum complex formation was demonstrated in the presence of 0.5 mM Ca2+. A mixture of anti-GPIIb and antiGPIIIa '-globulin appeared to detect a greater degree of membrane glycoprotein complex formation with fibrinogen than the sum detectable by using each antiserum alone at an identical concentration. Specificity and stoichiometry of GPIIb-GPIIIa complex formation with fibrinogen. Complex formation of GPIIb-GPIIIa with adsorbed fibrinogen was determined in the presence of excess fluid phase fibrinogen. Following the coating of fibrinogen (3 ;ig/ ml) on the microtitration plate, the platelet glycoprotein mixture (2.4 Mg/ml) was incubated with TrisTween buffer with 0.5 mM Ca21 in the presence of 6 jig/ml fibrinogen. The amount of GPIIb and GPIIIa that was detectable as a complex with the adsorbed fibrinogen was decreased practically to the control level (Table II) . The small amount of GPIIb and GPIIIa that complexed to adsorbed fibrinogen in the presence of soluble fibrinogen was considered "nonspecific" binding. No inhibition of GPIIb-GPIIIa complex formation with fibrinogen was detected when the experiments were repeated in the presence of comparable amounts of fluid phase purified human albumin.
Saturation of the binding or complexing of the glycoproteins to the fibrinogen was determined by plotting the specific binding (total minus nonspecific) of incremental amounts of GPIIb and GPIIIa to a fixed amount of adsorbed fibrinogen (Fig. 2) . Saturation was achieved at a GPIIb-GPIIIa concentration of 2.4 jg/ ml. The color generated in the ELISA by this amount of bound GPIIb-GPIIIa (35 X 10-4 AA405 min-') cor- ,gg/ml) in Tris-Tween with or without added Ca21 was added for 24 h at 4°C. The remaining steps were carried out as described in Fig. 1 . Control studies performed with antialbumin substituing for anti-GPIIb and anti-GPIIIa. o Fibrinogen (3 ug/ml) in coating buffer was applied to the plastic wells for 18 h, 4°C. After washing, the GPIIb-GPIIIa mixture (2.4 Mg/ml) in Tris-Tween Ca2" buffer was added alone or in the presence of fibrinogen (6 ,ug/ml) or albumin (12 ,ug/ml). The remaining steps were carried out as described in Fig. 1. responded to 19 ng GPIIb-GPIIIa bound (Fig. 1) . Using radiolabeled fibrinogen, the coating efficiency of fibrinogen at 3 ,tg/ml was 35.8%, corresponding to 215 ng bound to the well. Assuming a Mr of 235,000 for a 1:1 GPIIb-GPIIIa complex and Mr of 330,000 for fibrinogen, the data suggest a stoichiometric relationship of fibrinogen to GPIIb-GPIIIa of 8:1. The specificity of the GPIIb-GPIIIa interaction with fibrinogen was further studied by incubating GPIIbGPIIIa mixtures with adsorbed fibronectin, plasminogen, or factor VIII:AGN. The coating efficiency for these proteins to the microtitration plate was determined using '25I-labeled proteins and was comparable to that of fibrinogen. No evidence of complex formation was detected (Table III) . Platelet Fig. 1 . The extent of specific GPIIb-GPIIIa complex formation with adsorbed fibrinogen (total minus nonspecific) was plotted as a function of increasing GPIIbGPIIIa concentration. The proteins (6 ,g/ml) in coating buffer were applied to the plastic wells for 18 h, 4°C. After washing, the GPIIb-GPIIIa mixture (2.88 /g/ml) in Tris-Tween calcium buffer was added for 24 h, 4°C.
Platelet Glycoproteins IIb-IIIa Complex Formation with Fibrinogen
The remaining steps were carried out as described in Fig. 1. man erythrocyte membrane glycoproteins (lentil lectin affinity column eluate) also did not show any complex formation with adsorbed fibrinogen, using monospecific antisera to these proteins in an ELISA assay (Table IV) .
Effect of amino sugars and amino acids on GPIIbGPIIIa complex formation with fibrinogen. Previous studies have suggested that specific amino sugars such as glucosamine, mannosamine, and amino acids such as arginine block platelet lectin activity and may interfere with platelet fibrinogen binding (24, 25) . Glucosamine, mannosamine, and arginine significantly inhibited GPIIb-GPIIIa complex formation with fibrinogen (Table V) . In contrast, N-acetyl glucosamine, N-acetyl mannosamine, and glycine at similar concentrations had no effect.
Lack of complex formation using purified GPIIbGPIIIa. It has previously been demonstrated that the eluate from the lentil lectin affinity chromatgraphy of solubilized platelet membrane proteins contains other minor proteins in addition to GPIIb and GPIIIa (26) . These include GPIb and thrombospondin. Antisera raised to the purified GPIIb and GPIIIa isolated from SDS-PAGE gels appeared to be monospecific and did not react with thrombospondin or GPIb. The SDS-PAGE gel isolated platelet GPIIb and GPIIIa were Fig. 1 . The antisera to the individual proteins were used at 1:100 dilution. (Table VII) . Previous studies have shown that both anti-GPIIb and anti-GPIIIa Fab'2 fragments caused platelet agglutination, indicating that they were directed against platelet surface components (10). The reason for the increased binding detected in the presence of anti-GPIIb Fab'2 was not determined.
DISCUSSION
In this study we have demonstrated that a mixture of undenatured platelet membrane glycoproteins eluted from a lentil lectin affinity column forms a complex with human fibrinogen. Using monospecific antisera to isolated purified GPIIb and GPIIIa (10), we have demonstrated that platelet GPIIb and GPIIIa in the membrane glycoprotein mixture are the specific molecular components that complex with fibrinogen. The formation of the GPIIb-GPIIIa fibrinogen complex is calcium dependent, fibrinogen specific, saturable, and inhibited by specific amino sugars and amino acids. These observations suggest that GPIIb and GPIIIa, which probably exist in the platelet membrane as a macromolecular complex (3, 28, 29) , act under the proper physiologic circumstances as the fibrinogen binding site required for normal platelet aggregation. It is not clear from our studies whether GPIIb alone, GPIIIa alone, or the GPIIb-GPIIIa complex bears the actual binding site. The ELISA studies demonstrating complex formation were possible only using undenatured mixtures of the membrane glycoproteins. When GPIIb and GPIIIa were individually isolated by electrophoretic elution from SDS-PAGE gels, no complex formation was demonstrable (Table VI) . It is thus highly probable that the binding site(s) of the membrane glycoproteins was denatured in the process of purification. The premise is further supported by the fact that the monospecific antisera to GPIIb and GPIIIa neither inhibited platelet aggregation to physiologic stimuli (10) nor blocked fibrinogen binding by ADP stimulated platelets (Table VII) . The possibility should be considered that the binding of GPIIb-GPIIIa Platelet Glycoproteins IIb-IIIa Complex Formation with Fibrinogen 267 to fibrinogen is facilitated by an additional component or cofactor that is present in the lentil lectin eluate but is absent in the mixture of purified proteins. Kornecki et al. (27) have described a high affinity fibrinogen receptor present on normal as well as thrombasthenic platelets that is exposed by chymotrypsin. It is not known how this latter activity is related to the GPIIbGPIIIa system. Interestingly, a recently described monoclonal antibody to the platelet membrane GPIIb-GPIIIa complex also did not interfere with ADP or thrombin-induced platelet aggregation (28) . It is probable that these antibodies do not provide enough steric hindrance to indirectly block fibrinogen binding.
The stoichiometry of the fibrinogen GPIIb-GPIIIa interaction on the plastic microtitration plates suggests that one GPIIb-GPIIIa complex was bound per eight fibrinogen molecules-assuming a monomeric 1:1 relationship between GPIIb and GPIIIa. This stoichiometric relationship must be interpreted with some caution before extrapolating to the real biologic event. Thus these studies use a plastic surface with coated fibrinogen molecules. It is most probable that the adsorbed fibrinogen molecules are oriented in a highly random manner with significant steric restriction. Thus only a fraction of the bound fibrinogen may be functionally available for binding of the soluble GPIIbGPIIIa complex. These considerations make it probable that the 8:1 stoichiometry is an overestimation. A more biologically relevant experimental surface such as a liposome might be more appropriate for defining the true stoichiometry of this complex formation.
Presently available information from several different groups suggest that there is a single class of fibrinogen binding sites (6) (7) (8) estimated to be -40,000 per platelet. This estimation nicely fits the monoclonal antibody studies that identified -40,000 GPIIb-GPIIIa complexes per platelets (28) . Other groups have demonstrated fewer receptors with evidence of two classes of binding sites with different affinities (9, 30) . Further studies are required to determine whether additional platelet membrane constituents other than GPIIb and GPIIIa bind to fibrinogen after physiologic stimulation.
